News

Researcher from the Indiana University School of Medicine found that at well-child visits 4.4% of fathers reported symptoms of depression compared to 5% of mothers.

If these results are confirmed by future research, the use of blood eosinophil count tests could improve patient care and reduce asthma-associated healthcare costs.

After 18 months of treatment, Study 201 participants at the highest treatment dose demonstrated a statistically significant slowing of cognitive decline of 30% compared to placebo.

Researchers map family trees of cancer cells in acute myeloid leukemia to better understand how the cancer responds to new drug, enasidenib.

Patients in the intensive blood pressure treatment group had a 19% lower risk of developing mild cognitive impairment compared to those given standard treatment, according to the SPRINT MIND study.

New research highlights the potential of fetal gene therapy to prevent and cure neonatal lethal neurodegenerative diseases in humans in utero.

The ECDC is currently investigating a multi-country outbreak of listeriosis linked to frozen vegetables that has been ongoing since 2015.

A new company says urine tests can help physicians determine whether a patient at risk of HIV infection is adhering to their pre-exposure prophylaxis regimen.

New guidelines on the prevention and treatment of HIV in adults from the IAS-USA Panel highlight advances made since the 2016 guidelines, as well as the need for new strategies.

Researchers say that adding a common altitude sickness drug to the treatment protocol for patients with glioblastoma may improve the effectiveness of chemotherapy and extend survival in some patients.

The first human clinical trial to assess RNA therapy, QR-313, for the treatment of recessive dystrophic epidermolysis bullosa has been initiated.

Elagolix (Orlissa) is the first oral gonadotropin-releasing hormone antagonist specifically developed for women with moderate to severe endometriosis pain.

A study of pediatric patients with asthma admitted to emergency departments has determined that while rhinovirus is the most prevalent infection, it is the non-rhinovirus pathogens that are associated with an increased absolute risk of treatment failure.

Researchers found that just 18.4% of young women diagnosed at pediatric emergency departments with pelvic inflammatory disease received HIV and syphilis screening, despite their higher risk for those sexually transmitted infections.

A workgroup convened by the Alzheimer’s Association has developed a list of 20 recommendations regarding symptoms of Alzheimer’s disease and related forms of dementia.

Researchers find that a glucose-derived dietary supplement was able to increase muscle-force production in a Duchenne muscular dystrophy mouse model by 50% in 10 days.

PharmaKrysto Ltd. and Rutgers University, New Jersey, have entered into a licensing agreement for the development of PK10, a novel drug for the treatment of cystinuria.

The PocketECG Cardiac Rehabilitation System provides electrocardiography (ECG) monitoring and alerts during cardiac rehabilitation.

Phase 2a clinical trial commences for repurposed drug, SOM3355, for the treatment of Huntington’s disease.

Researchers found that enhanced disinfection with UV light in targeted rooms led to a decrease in hospital-wide incidence of C. difficile and vancomycin-resistant enterococci.

A review of literature on depression and anxiety in patients with heart failure reports that 21.5% have depressive symptoms and 19% meet the criteria for a depressive disorder—2 to 3 times higher than rates in the general population.

Stay up-to-date on the latest rare disease news by reading the top 5 articles of the week.

Researchers have discovered that a gene may be linked to neuromyelitis optica, a highly rare disease known to lead to blindness and paralysis.

The FDA has approved ivosidenib tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia who have a specific genetic mutation.

The US Food and Drug Administration (FDA) has granted an orphan drug designation to Corbus Pharmaceuticals Holdings, Inc’s lenabasum for the treatment of dermatomyositis.

One phase 2 study showed that RBX2660, a microbiota-based drug comprised of human stool, was effective in 77.8% of patients.

The US Food and Drug Administration (FDA) has granted fast track designation to galinpepimut-S (GPS) for the treatment of multiple myeloma.

The cerebrospinal fluid assays can detect biomarkers of Alzheimer disease and help clinicians diagnose AD before clinical symptoms appear.